Tobias Nordstrom, MD, PhD, presented “Clinical Trial of STHLM3 and MRI” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 21, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Nordstrom, Tobias “Clinical Trial of STHLM3 and MRI.” September 21, 2023. Accessed Aug 2024. https://grandroundsinurology.com/clinical-trial-of-sthlm3-and-mri/
Clinical Trial of STHLM3 and MRI – Summary
The clinical trial of STHLM3 and MRI, presented at the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 21, 2023, represents a significant advancement in prostate cancer diagnostics. This trial represents a pioneering effort to enhance the accuracy and efficiency of prostate cancer detection, addressing the limitations of current diagnostic methodologies.
The STHLM3 test, a multifaceted blood test incorporating protein biomarkers, genetic markers, and clinical data, aims to provide a more precise risk assessment for prostate cancer. Dr. Nordstrom compares the STHLM3 test to traditional prostate-specific antigen (PSA) testing, noting that the STHLM3 test offers superior specificity and sensitivity.
Dr. Nordstrom emphasizes the potential of combining STHLM3 with multiparametric MRI (mpMRI) to enhance diagnostic accuracy further. The trial’s protocol involves administering the STHLM3 test to identify individuals at elevated risk, who then undergo mpMRI to confirm and localize potential malignancies.
Preliminary results from the trial indicate a significant reduction in unnecessary biopsies and improved detection of clinically significant prostate cancers. Dr. Nordstrom highlights that this combined approach not only enhances diagnostic precision but also optimizes patient management by stratifying risk more effectively.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Clinical urologist and researcher dedicated to improve diagnostics and treatment of prostate cancer and other urological conditions. Tobias Nordström is a clinically active urologist, focusing on the detection and treatment of malignancies in the prostate and kidney, as well as treating general urological conditions. He started practicing urology in 2007 and has achieved degrees in General Surgery and Urology at Danderyd's Hospital. He was awarded Fellow of the European Board of Urology (FEBU) in 2015.
Tobias Nordström defended his thesis "Predicting Prostate Cancer- on the use of biomarkers in Prostate Cancer Diagnostics" in January 2015 after which he undertook international postdoctoral studies at University of California, San Francisco. He now combines clinical surgical practice at Danderyds Hospital with independent research at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. Centrepieces of his work includes leading guidelines development and implementing improvements in clinical care such as targeted prostate biopsies and imaging.
